Thierry Burnouf
#155,127
Most Influential Person Now
Researcher
Thierry Burnouf's AcademicInfluence.com Rankings
Thierry Burnoufcomputer-science Degrees
Computer Science
#8480
World Rank
#8913
Historical Rank
Data Science
#199
World Rank
#203
Historical Rank
Computational Linguistics
#1895
World Rank
#1915
Historical Rank
Machine Learning
#3481
World Rank
#3524
Historical Rank
Thierry Burnoufmathematics Degrees
Mathematics
#7147
World Rank
#9774
Historical Rank
Measure Theory
#1904
World Rank
#2319
Historical Rank
Download Badge
Computer Science Mathematics
Thierry Burnouf's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Thierry Burnouf Influential?
(Suggest an Edit or Addition)Thierry Burnouf's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. (1991) (510)
- Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use (1997) (381)
- Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? (2016) (342)
- Modern Plasma Fractionation (2007) (232)
- Reducing the risk of infection from plasma products: specific preventative strategies. (2000) (196)
- Blood-derived biomaterials and platelet growth factors in regenerative medicine. (2013) (195)
- In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. (2009) (192)
- Nanofiltration of plasma‐derived biopharmaceutical products (2003) (190)
- Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. (2014) (173)
- Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment (2014) (163)
- Treatment of severe acute respiratory syndrome with convalescent plasma. (2003) (156)
- Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance (2010) (144)
- Antivenoms for the treatment of snakebite envenomings: the road ahead. (2011) (137)
- The platelet-cancer loop. (2013) (135)
- Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion (2014) (134)
- Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI Concentrates (1994) (118)
- Platelet–Cancer Interactions (2014) (113)
- Extracellular Microvesicles as New Industrial Therapeutic Frontiers. (2019) (112)
- Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. (2001) (108)
- Antimicrobial activity of platelet (PLT)‐poor plasma, PLT‐rich plasma, PLT gel, and solvent/detergent‐treated PLT lysate biomaterials against wound bacteria (2013) (101)
- An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful? (2015) (99)
- Platelets effects on tumor growth. (2014) (93)
- Quantitative assessment of the kinetics of growth factors release from platelet gel (2008) (88)
- WHO Expert Committee on Biological Standardization. (1990) (87)
- Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma (2020) (86)
- Chromatography in plasma fractionation: benefits and future trends. (1995) (85)
- Expansion of adipose tissue mesenchymal stromal progenitors in serum‐free medium supplemented with virally inactivated allogeneic human platelet lysate (2011) (81)
- A Novel Technique Combining Platelet Gel, Skin Graft, and Fibrin Glue for Healing Recalcitrant Lower Extremity Ulcers (2010) (77)
- Properties of a Highly Punified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional Chromatography (1989) (74)
- Ebola virus convalescent blood products: Where we are now and where we may need to go (2014) (69)
- A Highly Purified Factor VIII:c Concentrate Prepared from Cryoprecipitate by Ion‐Exchange Chromatography (1991) (68)
- Assessment of the viral safety of antivenoms fractionated from equine plasma (2004) (67)
- Transfusion-related immunomodulation and cancer. (2017) (64)
- The role of microparticles in inflammation and transfusion: A concise review. (2015) (63)
- Strengthening antivenom production in Central and South American public laboratories: report of a workshop. (2007) (62)
- Platelet microparticles and cancer: An intimate cross-talk. (2015) (61)
- Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. (2017) (61)
- Biochemical and Physical Properties of a Solvent‐Detergent‐Treated Fibrin Glue (1990) (59)
- A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming. (2014) (58)
- Solvent‐detergent filtered (S/D‐F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system (2010) (58)
- Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and disease. (2015) (57)
- Reversed-phase high-performance liquid chromatography of reduced glutenin, a disulfide-bonded protein of wheat endosperm☆ (1984) (56)
- Catalase-Modulated Heterogeneous Fenton Reaction for Selective Cancer Cell Eradication: SnFe2O4 Nanocrystals as an Effective Reagent for Treating Lung Cancer Cells. (2017) (55)
- Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products (2018) (54)
- Chromatographic Preparation of a Therapeutic Highly Purified von Willebrand Factor Concentrate from Human Cryoprecipitate (1992) (53)
- Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation (2019) (53)
- Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion. (2019) (53)
- Impact of Transfusion on Cancer Growth and Outcome (2016) (53)
- Treatment of Nonhealing Diabetic Lower Extremity Ulcers with Skin Graft and Autologous Platelet Gel: A Case Series (2013) (51)
- Solvent/detergent treatment of platelet concentrates enhances the release of growth factors (2008) (50)
- Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. (2019) (49)
- Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing RANKL/OPG ratio and depressing the TLR4/MyD88 signaling pathway (2018) (47)
- Human platelet lysate current standards and future developments (2019) (47)
- Current strategies to prevent transmission of prions by human plasma derivatives. (2006) (46)
- Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. (2016) (45)
- Glutenin subunits of genetically related European hexaploid wheat cultivars: Their relation to bread-making quality (2004) (45)
- Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries (2020) (45)
- A therapeutic, highly purified factor XI concentrate from human plasma (1992) (43)
- Prospective Therapeutic Applications of Platelet Extracellular Vesicles. (2020) (41)
- Large‐Scale Production and Properties of a Solvent‐Detergent‐Treated Factor IX Concentrate from Human Plasma (1988) (40)
- Place of nanofiltration for assuring viral safety of biologicals (2005) (40)
- A virally inactivated functional growth factor preparation from human platelet concentrates (2009) (40)
- International Forum on GMP‐grade human platelet lysate for cell propagation: summary (2018) (40)
- Reversed-phase high-performance liquid chromatography of durum wheat gliadins: Relationships to durum wheat quality (1984) (39)
- A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable‐bag system (2006) (39)
- Recombinant plasma proteins (2011) (39)
- Plasma fractionation issues. (2009) (39)
- A Gelatin Hydrogel-Containing Nano-Organic PEI–Ppy with a Photothermal Responsive Effect for Tissue Engineering Applications (2018) (38)
- Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. (2012) (38)
- Wheat varietal identification and genetic analysis by reversed-phase high-performance liquid chromatography (1984) (37)
- A minipool process for solvent–detergent treatment of cryoprecipitate at blood centres using a disposable bag system (2006) (37)
- Blood transfusion in sub‐Saharan Africa: understanding the missing gap and responding to present and future challenges (2018) (35)
- A Call for Incorporating Social Research in the Global Struggle against Snakebite (2015) (35)
- Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue (2009) (35)
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes (2022) (34)
- Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates (2019) (34)
- Duration of red blood cell storage and inflammatory marker generation. (2017) (34)
- Ebola: a call for blood transfusion strategy in sub-Saharan Africa (2014) (33)
- Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease. (2017) (32)
- Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges. (2020) (32)
- The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways (2017) (32)
- Nanofiltration of single plasma donations: feasibility study (2003) (31)
- Self‐Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy (2017) (31)
- A novel core fractionation process of human plasma by expanded bed adsorption chromatography. (2010) (30)
- Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. (1992) (30)
- Development of an enzyme-linked immunosorbent assay for human plasma inter-alpha-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. (1996) (29)
- Ex vivo Expansion of Bovine Corneal Endothelial Cells in Xeno-Free Medium Supplemented with Platelet Releasate (2014) (29)
- Albumin batches and B19 parvovirus DNA (1995) (29)
- Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries (2015) (29)
- Biochemical and Biological Properties of an α1‐Antitrypsin Concentrate (1987) (29)
- Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. (2016) (29)
- Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment (2015) (28)
- Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. (2001) (28)
- Cranioplasty using osteoconductive scaffold and platelet glue. (2008) (28)
- Human platelet concentrates: a source of solvent/detergent‐treated highly enriched brain‐derived neurotrophic factor (2012) (27)
- Preparation and Properties of a Therapeutic Inter‐Alpha‐Trypsin Inhibitor Concentrate from Human Plasma (1994) (27)
- Anti‐inflammatory effects of platelet biomaterials in a macrophage cellular model (2015) (27)
- A pasteurized therapeutic plasma. (1992) (27)
- COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors (2021) (27)
- Virucidal heat‐treatment of single plasma units: a potential approach for developing countries (2000) (25)
- Platelet‐derived growth factor‐AB and transforming growth factor‐β1 in platelet gels activated by single‐donor human thrombin (2004) (24)
- Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). (2019) (23)
- Protein composition and activation markers in plasma collected by three apheresis procedures (2003) (23)
- Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma. (1998) (23)
- Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems (2008) (23)
- Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer (2020) (22)
- An overview of plasma fractionation (2018) (22)
- Purification of IgG and albumin from human plasma by aqueous two phase system fractionation (2012) (22)
- Use of COVID‐19 convalescent plasma in low‐ and middle‐income countries: a call for ethical principles and the assurance of quality and safety (2020) (21)
- Identification of wheat cultivars and prediction of quality by reversed-phase high-performance liquid chromatographic analysis of endosperm storage proteins (1987) (21)
- Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model (2013) (21)
- Effect of cell culture biomaterials for completely xeno-free generation of human induced pluripotent stem cells. (2019) (20)
- Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop (2020) (20)
- Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. (2014) (20)
- Chromatographic removal of viruses from plasma derivatives. (1993) (20)
- [Plasma fractionation in the world: current status]. (2007) (20)
- Circulatory-cell-mediated nanotherapeutic approaches in disease targeting. (2017) (19)
- PDA Technical Report No. 41: Virus filtration (2005) (19)
- A novel virally inactivated human platelet lysate preparation rich in TGF‐β, EGF and IGF, and depleted of PDGF and VEGF (2010) (18)
- A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots. (2019) (18)
- Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG (2014) (18)
- Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. (2007) (18)
- Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. (2012) (18)
- Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. (2015) (18)
- Pharmacokinetic study of minipooled solvent/detergent‐filtered cryoprecipitate factor VIII (2011) (18)
- Red blood cell transfusion and outcome in cancer. (2017) (17)
- Comparison of three human platelet lysates used as supplements for in vitro expansion of corneal endothelium cells. (2017) (17)
- Human Platelet Antigen Alleles in 998 Taiwanese Blood Donors Determined by Sequence-Specific Primer Polymerase Chain Reaction (2013) (17)
- Chromosomal control of glutenin subunits in aneuploid lines of wheat: analysis by reversed-phase high-performance liquid chromatography (1985) (17)
- Residual cell content in plasma produced by three centrifugal apheresis procedures (2003) (16)
- Comparison of High Purity Factor IX Concentrates and a Prothrombin Complex Concentrate in a Canine Model of Thrombogenicity (1991) (16)
- Assessment of complement activation during membrane‐based plasmapheresis procedures (2004) (16)
- Chromosomal control of wheat gliadin: analysis by reversed-phase high-performance liquid chromatography (1985) (16)
- The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates (2019) (16)
- Dengue virus inactivation by minipool TnBP/Triton X‐45 treatment of plasma and cryoprecipitate (2013) (16)
- A chromatographically purified human TGF‐β1 fraction from virally inactivated platelet lysates (2011) (15)
- Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. (2014) (15)
- Delayed vasal reanastomosis in rats: comparison of a microsurgical technique and a fibrin-glued procedure. (1996) (15)
- A double‐virally‐inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells (2019) (15)
- Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past. (2019) (15)
- Impact of solvent/detergent treatment of plasma on transfusion‐relevant bacteria (2012) (15)
- Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography (2015) (15)
- New methods of plasma fractionation – a presentation of the ‘mini‐pool’ fractionation procedure developed in Egypt (2009) (15)
- Biochemical and Biological Properties of an a 1 -Antitrypsin Concentrate (1987) (14)
- A virally inactivated platelet‐derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets (2010) (14)
- Influence of ethanol on the release of growth factors in human blood-derived platelet gels. (2010) (14)
- “Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed! (2014) (14)
- Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing. (2015) (14)
- Preparation and viral inactivation of cryoprecipitate in blood banks in resource‐limited countries (2007) (14)
- Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome (2016) (14)
- Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. (2007) (13)
- Single-Donor Allogeneic Platelet Fibrin Glue and Osteoconductive Scaffold in Orbital Floor Fracture Reconstruction (2012) (13)
- Large-scale preparation of highly purified human C1-inhibitor for therapeutic use. (1994) (13)
- Evaluation of a Fibrin Sealant Free of Bovine-Derived Components in an Experimental Vas Anastomosis Study (2000) (13)
- Plasma proteins: Unique biopharmaceuticals – Unique economics (2005) (13)
- Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses (2020) (13)
- Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro (2020) (13)
- Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells. (2019) (13)
- Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment (2021) (12)
- [Use of a biological glue in partial pulmonary excision surgery. Results of a controlled trial in 50 patients]. (1991) (12)
- Single‐use technology for solvent/detergent virus inactivation of industrial plasma products (2016) (11)
- Blood products: unmet needs for essential medicines. (2019) (11)
- Content and functional activity of von Willebrand factor in apheresis plasma (2004) (11)
- International Forum on GMP‐grade human platelet lysate for cell propagation (2018) (11)
- Human platelet lysates for human cell propagation (2020) (11)
- Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. (2009) (11)
- TnBP⁄Triton X-45 Treatment of Plasma for Transfusion Efficiently Inactivates Hepatitis C Virus (2015) (11)
- Vasal Reanastomosis Using Fibrin Glue Combined with Sutures: Which Combination of Sutures in a Delayed Protocol? (1998) (11)
- Human plasma‐derived immunoglobulin G fractionated by an aqueous two‐phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity (2015) (11)
- NanoBioAnalytical characterization of extracellular vesicles in 75-nm nanofiltered human plasma for transfusion: A tool to improve transfusion safety. (2019) (11)
- The microbiome and transfusion in cancer patients. (2017) (10)
- Value of Virus Filtration as a Method for Improving the Safety of Plasma Products (1996) (10)
- The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update (2020) (10)
- Inheritance of glutenin subunits in F1 seeds of reciprocal crosses between European hexaploid wheat cultivars (2004) (10)
- Chromatographic purification and properties of a therapeutic human protein C concentrate. (2003) (10)
- Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion. (2016) (10)
- New approaches for manufacturing plasma derivatives (2014) (9)
- The effect of human platelet lysate on the differentiation ability of human adipose-derived stem cells cultured on ECM-coated surfaces. (2019) (9)
- International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID‐19 pandemic (2022) (9)
- Jet nebulisation: Influence of dynamic conditions and nebuliser on nebulisation quality. Application to the α 1 protease inhibitor (1997) (9)
- Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells (2020) (9)
- Purification of human ceruloplasmin as a by-product of C1-inhibitor. (2000) (9)
- Pathogen reduction technique for fresh‐frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems (2011) (9)
- Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. (2016) (9)
- Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardization (2016) (8)
- Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. (2022) (8)
- Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer (2021) (8)
- An approach to outreach patients with von Willebrand disease in Egypt by targeting women with heavy menstrual bleeding and/or bleeding symptoms (2014) (8)
- Plasma fractionation in Asia–Pacific: challenges and perspectives (2011) (8)
- LOCAL HEMOSTATIC BLOOD PRODUCTS IN HEMOPHILIA CARE: FIBRIN SEALANT AND PLATELET GEL (2008) (8)
- A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress. (2021) (7)
- Platelets, Coagulation and Cancer: Multifaceted Interactions (2012) (7)
- Influence of formulation on jet nebulisation quality of α1 protease inhibitor (1999) (7)
- Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length (2018) (7)
- Blood cell-derived microvesicles with potential pathogenic roles in therapeutic blood components and specialized diagnostic tools in diseases. (2015) (7)
- Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. (2021) (7)
- Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward? (2019) (7)
- Bitter progress in the treatment of haemophilia A in low-income countries. (2018) (7)
- Delayed vasovasostomy: experimental study using fibrin glue. (1997) (7)
- Lessons learned in the collection of convalescent plasma during the COVID‐19 pandemic (2021) (7)
- Convalescent Plasma and the Dose of Ebola Virus Antibodies. (2017) (6)
- Current status and new developments in the production of plasma derivatives (2016) (6)
- Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (2016) (6)
- Gliadin Analysis by Reversed-Phase High-Performance Ijquid Chromatography : Optimization of Extraction Conditions (2007) (6)
- [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems]. (2008) (6)
- NEW TRENDS IN PLASMA FRACTIONATION AND PLASMA PRODUCTS TRENDS IN PLASMA FRACTIONATION (1994) (6)
- Platelet transfusion in thrombocytopenic cancer patients: Sometimes justified but likely insidious. (2017) (6)
- Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor. (1999) (5)
- Strategy of Virus Removal / Inactivation of Plasma-Derived Products : Interest of Nanofiltration as a New Virus Elimination Method (1994) (5)
- COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy. (2021) (5)
- Reflections on multiple strategies to reduce transfusion in cancer patients: A joint narrative. (2017) (5)
- Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents. (2009) (5)
- Platelet and extracellular vesicles in COVID-19 infection and its vaccines (2022) (5)
- Natural Scrub Typhus Antibody Suppresses HIV CXCR4(X4) Viruses (2013) (5)
- Experience with COVID‐19 convalescent plasma provides vital guidance to future pandemics (2022) (5)
- Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. (2021) (4)
- Improving haemophilia therapy in developing countries: virus‐safe cryoprecipitate (2019) (4)
- International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary (2021) (4)
- The multifaceted role of platelets in mediating brain function (2022) (4)
- New trends in plasma fractionation and plasma products. (1994) (4)
- Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate. (2021) (4)
- Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2 (2022) (4)
- Stepwise access to safe plasma proteins in resource‐constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop (2022) (3)
- Standardized human platelet lysate supplement demonstrates to be an effective, serum-free, xeno-free, FBS replacement for culturing AT-/BM-/and UC-mesenchymal stem cells (2014) (3)
- Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity. (2021) (3)
- Iridium Oxide Nanoparticle–Protein Corona Neural Interfaces with Enhanced Electroactivity and Bioactivity Enable Electrically Manipulatable Physical and Chemical Neuronal Activation (2021) (3)
- Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections (2020) (3)
- Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III. (1987) (3)
- Evaluation of the effectiveness of different antifoams for an α1 PI solution (1997) (3)
- AIDS--past and future. (2002) (3)
- Biological and Biochemical Assays to Ensure the Quality and Safety of Plasma-Derived Products: Factor VIII Concentrates (2007) (3)
- Transmission of scrub typhus by blood transfusion? (2001) (3)
- New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement. (2019) (3)
- Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience (2018) (3)
- A comparison between endoscopic injection of bleeding esophageal varices using ethanolamine oleate and fibrin glue sealant in patients with bilharzial liver fibrosis. (1999) (3)
- Purification of factor VIII/von Willebrand factor from human plasma on immobilized lentil lectin. (1994) (3)
- Principles of haemophilia care: The Asia‐Pacific perspective. (2018) (2)
- Fabrication of co-electrodeposition of plasma proteins/iridium oxide hybrid films (2018) (2)
- Neuroprotective activity of a virus‐safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models (2022) (2)
- What can be learned in the snake antivenom field from the developments in human plasma derived products? (2018) (2)
- In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration (2022) (2)
- SARS-CoV-2 and cancer: the intriguing and informative cross-talk (2022) (2)
- Regenerative effect of expired platelet concentrates in human therapy: An update. (2022) (2)
- Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada. (2006) (2)
- Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth media supplemented with 10% human platelet lysate (2021) (2)
- Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion (2016) (2)
- Commentary on technical specifications and safety requirements of serum eye drops: Keeping a close eye on the content in cytokines. (2016) (2)
- Convalescent Plasma for Ebola Virus Disease. (2016) (2)
- Can the administration of platelet lysates to the brain help treat neurological disorders? (2022) (2)
- International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Responses (2021) (2)
- Strategies to Preclude Hepatitis C Virus Entry (2017) (2)
- Erratum: Residual cell content in plasma produced by three centrifugal apheresis procedures (Transfusion (2003) 43 (1522-1526)) (2004) (2)
- Quality of plasma and its fractionation (2008) (2)
- Plasma fractionation (2012) (2)
- Annals of Blood special issue on plasma fractionation (2018) (1)
- [Procedure for the isolation of human plasma fibronectin (author's transl)]. (1982) (1)
- Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage (2016) (1)
- CO-INFECTION BY HIV-1 AND SCRUB TYPHUS MAY LEAD TO DECREASED VIRAL LOAD AND PREFERENTIAL SUPPRESSION OF X4 VIRUSES (2004) (1)
- Blood cell-derived microparticles and nanoparticles: Multifaceted topics for research. (2015) (1)
- [Plasma fractionation. Progress, problems and perspectives]. (1994) (1)
- Viral safety of plasma products – do we have zero risk? (2001) (1)
- Process for the preparation of purified albumin (1990) (1)
- The Current Global Status and Production Trends of Plasma Fractionation (2017) (1)
- Affinity Chromatography–Fractionated and DNA‐Engineered Plasma Proteins (2009) (1)
- Recovered plasma for fractionation: call for quality standards to end wastage (2019) (1)
- Renal graft in a protein C deficient patient under protein C concentrate infusion (1990) (1)
- Development of electrical powerless system for blood separation and coagulation time measurement (2020) (1)
- BLOOD-DERIVED, TISSUE ENGINEERING BIOMATERIALS (2004) (1)
- Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop. (2022) (0)
- Current strategies aimed at prevention of viral contamination of coagulation factor concentrates (2008) (0)
- Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now! (2023) (0)
- Reply: LETTERS TO THE EDITOR (2004) (0)
- Process for purification chromatographic pathway proteins, including factor viii, and the products obtained (1988) (0)
- Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas, y su utilizacion terapeutica. (1988) (0)
- A process for producing a highly purified human factor IX concentrates and other plasma proteins (1988) (0)
- Sources of guidance on collection and use of COVID-19 convalescent plasma especially relevant to low- and middle- income countries (2020) (0)
- Industrial scale production of high-purity standardized human von willebrand factor concentrate suitable for therapy (1992) (0)
- Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies (2023) (0)
- A process for the production on an industrial scale by a standardized concentrate of human von Willebrand factor with a meg (1992) (0)
- Subject Index Vol. 65, 2000 (2000) (0)
- Chromatographic separation of plasma proteins, mainly of factor VIII, von Willebrand factor and of fibronectin fibrinogen. (1989) (0)
- A process for separating Factor VIII, fibrinogen, fibronectin and von Willebrand Factor of human or animal plasma and factor VIII obtained by the process (1990) (0)
- Quality Control and Release Procedures for Products Derived from Human Blood or Human Plasma Application to Pasteurized Plasma (1994) (0)
- Protein concentrate coagulable by thrombin, its process of preparation and its use as a biological glue (1987) (0)
- Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps (2021) (0)
- Preparation of human factor IX concentrate of high purity and of other plasma proteins, and their therapeutic use. (1988) (0)
- PREPARATION PROCESS SCALE INDUSTRIAL CONCENTRATE OF A HUMAN FACTOR VON WILLEBRAND standardized, VERY HIGH PURITY, SUITABLE THERAPEUTIC USE. (1992) (0)
- Method of producing a concentrate coagulable of platelet growth factors (2009) (0)
- National Blood Foundation 2021 Research and Development summit: Discovery, innovation, and challenges in advancing blood and biotherapies (2022) (0)
- WHO Expert Committee on Biological Standardization. (2004) (0)
- Concentrate of high pure human factor ix, other blood plasma protein and therapeutic usage thereof (1988) (0)
- Iridium Oxide Nanoparticle–Protein Corona Neural Interfaces with Enhanced Electroactivity and Bioactivity Enable Electrically Manipulatable Physical and Chemical Neuronal Activation (Adv. Mater. Interfaces 16/2021) (2021) (0)
- Abstract 6723: Application of in vitro drug screening of circulating tumor cells in pediatric glioma therapy (2023) (0)
- A process for the preparation of immunoglobulin G concentrate (1994) (0)
- [Virus inactivation in plasma fractions for therapeutic use]. (1987) (0)
- Lysate containing inactivated platelet growth factors depleted PDGF and VEGF and their method of preparation (2010) (0)
- The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates (2019) (0)
- Acknowledgement to Reviewers (2018) (0)
- Process for the viral inactivation of plasmatic products by supercritical or subcritical fluids. (1993) (0)
- Preparation of human factor IX concentrate of high purity and other plasma proteins. (1988) (0)
- Foerfarande Foer framstaellning of the purified and albuminloesningar. (1990) (0)
- Procedures for preventing infectious risks from plasma products (2000) (0)
- On-chip detection, sizing and proteomics of extracellular vesicles (2018) (0)
- [Valve of a freeze-dried gelatin-agarose combination in selective extraction of fibronectin from human plasma]. (1981) (0)
- need to go (2014) (0)
- Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop (2020) (0)
- Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections (2020) (0)
- Process for the preparation of concentrates of von Willebrand factor human very high purity, a suitable therapeutic use. (1991) (0)
- Multifaceted regenerative lives of ‘expired’ platelets (2018) (0)
- A process for the preparation of a concentrate of Factor VIII-von Willebrand factor complex from whole blood clotting plasma. (1990) (0)
- A process for producing immunoglobulin G concentrate (1994) (0)
- Process for producing immunoglobulins g concentrate. (1994) (0)
- [Industrial pasteurization of plasma and criteria of quality]. (1993) (0)
- WHO Expert Committee on Biological Standardization. (2004) (0)
- Process for the preparation of blood coagulation factor VIII and von Willebrand factor complex concentrate kokoplasmasta (1990) (0)
- Biological and Rheological Properties of a Virally Inactivated Fibrin Glue (Biocol®): Comparison to an Autologous Fibrin Glue (2020) (0)
- Meet Our Editorial Board Member (2019) (0)
- A process for industrial scale production of a concentrate of highly purified, standardized human von Willebrand factor, which is suitable for therapeutic use (1992) (0)
- Blood transfusion in autoimmune rheumatic diseases. (2022) (0)
- Reply (2004) (0)
- Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature (2021) (0)
- Plasma proteins in chromatographic separation (1990) (0)
- Advances in Media Formulations for Clinical-Scale Expansion of Cells (2018) (0)
- Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (2022) (0)
- Vas anastomosis: Fertility evaluation of a bovine-free component fibrin-glued procedure (1997) (0)
- Production of high-gereingtem human factor IX and other plasma protein concentrates and their therapeutic use. (1988) (0)
- Preparation of improved bioactive tissue adhesives using autologous human thrombin (2004) (0)
- Process for the industrial scale preparation of a concentrate of Willebrand factor human standard very high purity suitable for therapeutic use. (1992) (0)
- Process for standardized human, having a high purity of the von Willebrand factor concentrate for the preparation of (1992) (0)
- A process for producing on an industrial scale of a concentrate of highly purified, standardized human von Willebrand factor, which is suitable for therapeutic use (1992) (0)
- Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer (2020) (0)
- Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients (2021) (0)
- A process for the preparation of a concentrate of Factor VIII-von Willebrand factor complex from clotting whole plasma. (1990) (0)
- Chromatographic separation of plasma proteins, especially of Factor VIII, von Willebrand factor, fibronectin and fibrinogen. (1989) (0)
- A method of separating the plasma proteins and plasmaproteinkoncentrater obtained by the method (1990) (0)
- A process for preparing a human factor IX concentrates and other plasma proteins as well as the therapeutic use thereof (1988) (0)
- Method for preparation of purified albumin solutions (1989) (0)
- WHO Expert Committee on Biological Standardization. (2004) (0)
- Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies. (2023) (0)
- Nanofiltration of extracellular vesicles from human plasma & their on-chip qualification and quantification with a NanoBioAnalytical platform (2018) (0)
- [Validation of rheological properties of fibrin glue: Biocol-Human Thrombin]. (1994) (0)
- WHO Expert Committee on Biological Standardization. (2013) (0)
- Plasma for fractionation: looking at its safety from a comprehensive angle (2016) (0)
- Contents Vol. 65, 2000 (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thierry Burnouf?
Thierry Burnouf is affiliated with the following schools:
